Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best NASDAQ Stocks to Buy with Huge Upside Potential. On September 9, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced five-year follow-up results from its phase 3 EMPOWER-Lung 3 trial.

The trial tested Libtayo combined with platinum-based chemotherapy versus chemotherapy alone and was meant for adults with advanced or metastatic non-small cell lung cancer without EGFR, ALK, or ROS1 mutations.

The results showed sustained survival benefits, with patients receiving Libtayo plus chemotherapy showing a 19.4% chance of survival at five years. The survival rate is notable, as it is more than double the 8.8% survival rate of chemotherapy alone. Moreover, the safety remained consistent with earlier reports. The results reinforce Libtayo plus chemotherapy as an effective first-line treatment option for advanced NSCLC.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.